

REMARKS

The Examiner's Office Action mailed February 4, 2009, which rejected all pending claims, has been reviewed. Reconsideration in view of the foregoing remarks is respectfully requested. Moreover, Applicants have reviewed the Office Action of February 4, 2009, and submit that the following Remarks are responsive to all points raised therein. Applicants believe that currently pending claims 8-12 are now in form for allowance.

Status of Claims

Claims 8-12 are pending in the application. No new matter has been added.

Rejection of Claims 8-12 under 35 USC § 102(e)

Reconsideration is requested of the rejection of claims 2-8 under §102(e) as being unpatentable over Arther (US Patent Publication No. 20020103233).

Even if two patent applications have different inventive entities, it does not necessarily mean that the earlier filed patent application is prior art to the later filed patent application. The issue becomes who invented the subject matter. In particular, if the disclosure in the earlier filed patent application is the later filed Applicant's own previous work, Applicant may be able to overcome a *prima facie* case of anticipation over the first filed application with a declaration under 37 CFR 1.132.¹

Applicants have once again attached two declarations submitted originally with the Response dated December 18, 2007, one by one of the inventors of the present application, Kirkor Sirinyan, and one by the inventor of US Patent Application No. 09/727,117 (US Patent Publication No. 20020103233), Robert Arther. From these declarations it is clear that the disclosure included in US Application No. 09/727,117, in particular in regards to a formulation that includes N-methylpyrrolidone (NMP) was conceived by the Applicant of the present

¹ MPEP 2136.05; See *In re Mathews*, 408 F.2d 1393, 161 USPQ 276 (CCPA 1969).

invention, Kirkor Sirinyan, and is Applicant's own work. As such, the disclosure in Arther is not prior art to the present application.

For all the reasons stated above, Arther does not anticipate claim 8. Claims 9-12 depend directly or indirectly from claim 8 and as such are patentable over Arther.

Conclusion

In view of the above, Applicants respectfully submit that the pending claims are novel and not obvious over the cited reference and request withdrawal of all rejections and allowance of the claims.

The Commissioner is hereby authorized to charge any fee deficiency or credit any overpayment in connection with this amendment to Deposit Account No. 50-4260.

Respectfully submitted,
/JESSICA MONACHELLO/
Jessica Monachello
Reg. No. 58,015
BAYER HEALTHCARE LLC
P.O. Box 390
Shawnee Mission, KS 66201
Tel: 913-268-2038
Fax: 913-268-2889